Video Experimental Relacionado
Updated: Jun 23, 2026
12:19
Analysis of Cell Cycle Position in Mammalian Cells
Published on: January 21, 2012
E2F1 reprime la transcripción de la beta-catenina y es antagonizada tanto por pRB como por CDK8
Erick J Morris1, Jun-Yuan Ji, Fajun Yang
1Laboratory of Molecular Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, 13th Street, Building 149, Charlestown, Massachusetts 02129, USA.
Nature
|September 17, 2008
Resumen
El factor de transcripción E2F1 inhibe la actividad del factor beta-catenina/células T (TCF), promoviendo la apoptosis. Los tumores colorrectales mantienen RB1 y amplifican CDK8 para suprimir E2F1, mejorando la proliferación impulsada por la beta-catenina.
Área de la Ciencia:
- Biología Molecular Biología Molecular
- Biología del cáncer Biología del cáncer.
- La señalización celular de las células.
Sus antecedentes:
- El factor de transcripción E2F1, un objetivo aguas abajo de la proteína supresora de tumores de retinoblastoma (pRB), juega un papel crítico en la regulación de la proliferación celular y la apoptosis.
- La señalización del factor beta-catenina/célula T (TCF) es crucial para la proliferación aberrante observada en muchos tipos de cáncer, particularmente en los tumores colorrectales.
Objetivo del estudio:
- Para investigar el papel inhibidor de E2F1 en la transcripción dependiente de la beta-catenina/TCF.
- Para dilucidar los mecanismos por los cuales E2F1 influye en el comportamiento de las células tumorales colorrectales.
- Para entender cómo los tumores colorrectales evaden la apoptosis mediada por E2F1 y mantienen la proliferación.
Principales métodos:
- Evaluó el efecto inhibidor de E2F1 en la actividad transcripcional beta-catenina/TCF.
- Examinó el impacto de la desregulación de E2F1 en los objetivos de beta-catenina, como c-MYC.
- Investigó el papel de la cinasa-8 dependiente de ciclina (CDK8) en la modulación de la actividad de E2F1 y la señalización de la beta-catenina.
Principales resultados:
- E2F1 fue identificado como un inhibidor potente y específico de la transcripción dependiente de beta-catenina/TCF, contribuyendo a la apoptosis inducida por E2F1.
- La desregulación de E2F1 suprimió la actividad de la beta-catenina independientemente de APC/GSK3, lo que condujo a una expresión reducida de c-MYC.
- Los tumores colorrectales mantienen RB1 y amplifican CDK8, que reprime la actividad de E2F1, protegiendo así la señalización beta-catenina/TCF.
Conclusiones:
- La inhibición de E2F1 de la señalización de la beta-catenina / TCF es un mecanismo clave que contribuye a la apoptosis inducida por E2F1.
- Las células tumorales colorrectales utilizan la retención de RB1 y la amplificación de CDK8 para suprimir E2F1, promoviendo la proliferación impulsada por la beta-catenina.
- Estos hallazgos proporcionan información sobre la intrincada interacción entre E2F1, beta-catenina y CDK8 en la tumorigénesis colorrectal.
Más Videos Relacionados
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
12:26Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
Videos de Conceptos Relacionados
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
01:52Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
02:23Master Transcription Regulators
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:23Catenins
Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...